Hackshaw MD, Bui CL, Ladner A, Tu N, Zahidu I, Ritchey ME, Salas M. Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumab post-trastuzumab gastric cancer. Cancer Treat Res Commun. 2020;24(2020). doi: 10.1016/j.ctarc.2020.100189
Ritter A, Mellor R, Chalmers J, Sunderland M, Lancaster K. Key considerations in planning for substance use treatment: estimating treatment need and demand. J Stud Alcohol Suppl. 2019 Jan;Supp1 18:22-30. doi: 10.15288/jsads.2019.s18.22
Hunter JE, Arnold KA, Cook JE, Zepp J, Gilmore MJ, Rope AF, Davis JV, Bergen KM, Esterberg E, Muessig KR, Peterson SK, Syngal S, Acheson L, Wiesner G, Reiss J, Goddard KAB. Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam Cancer. 2017 Jul;16(3):377-87. doi: 10.1007/s10689-017-9972-2
Ara R, Basarir H, Ward SE. Principles of health economic evaluations of lipid-lowering strategies. Curr Opin Lipidology. 2012 Aug;23(4):271-81. doi: 10.1097/MOL.0b013e32835423d9
Huang K, Gutierrez LP, Bulow S, Gallinger S, Castells A, Eagle CJ, Church JM. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. Fam Cancer. 2011 Jun 1;10(2):303-8.
Mangel AW, Williams VSL. Asimadoline in the treatment of irritable bowel syndrome. Expert Opin Investig Drugs. 2010 Oct 1;19(10):1257-64.
Vitolins MZ, Anthony M, Burke GL. Soy protein isoflavones, lipids and arterial disease. Curr Opin Lipidology. 2001 Aug;12(4):433-7.